Puma Biotechnology (PBYI) Cash from Operations (2010 - 2026)

Puma Biotechnology has reported Cash from Operations for 17 years, with the latest figure at 15400000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 326.36% year-over-year to 15400000.0; the trailing twelve-month figure through Mar 2026 stood at 53588000.0 (up 71.3% YoY), and the FY2025 full-year result was 41800000.0, up 7.41% from the prior year.
• Cash from Operations for Q1 2026 stood at 15400000.0, up from 14417000.0 in the prior quarter.
• The five-year high for Cash from Operations was 17259000.0 in Q3 2022, with the low at 26895000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 6311764.71 across 5 years, with a median of 10455000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 18648.65% — and 2025, when it jumped 1271.18%.
• Puma Biotechnology's Cash from Operations stood at 7683000.0 in 2022, then surged by 36.08% to 10455000.0 in 2023, then jumped by 49.28% to 15607000.0 in 2024, then retreated by 7.62% to 14417000.0 in 2025, then advanced by 6.82% to 15400000.0 in 2026.
• The last three Cash from Operations figures came in at 15400000.0 (Q1 2026), 14417000.0 (Q4 2025), and 9689000.0 (Q3 2025), per Business Quant data.